CVSBy Calypso Research7 min read

CVS Health Corporation (CVS) Q4 2025 Earnings Analysis

CVS Sees Growth Prescription with $105.7B Revenue Fill

Key Takeaways

CVS Health Corporation (CVS) reported Q4 2025 earnings with revenue of $105.7B, representing a +8.2% year-over-year change. The stock moved -0.2% on earnings day.

The bull case: CVS leverages MA margin recovery, resilient PBM economics, and scalable tech-enabled retail and engagement platforms to unlock its embedded earnings power and sustain mid-teens EPS growth through 2028.

The bear case: Persistent regulatory and reimbursement pressure in MA and PBM, combined with elevated medical trends and heavy tech investment, prevent CVS from achieving target margins and its long-term earnings growth algorithm.

Financial Highlights

  • Revenue: $105.7B (+8.2% YoY)
  • Gross Profit: $13.6B (12.8% margin, -0.4% YoY)
  • Operating Income: $2.1B (2.0% margin, -0.4% YoY)
  • Net Income: $2.9B
  • TTM Revenue: $402.1B

Stock Performance

  • Earnings Day Move: -0.2%
  • Year-to-Date: -3.9%
  • 1-Year Return: +22.2%
  • vs. S&P 500 (since earnings): -7.1%
  • vs. Nasdaq (since earnings): -4.2%

View live CVS data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from CVS Health Corporation's Q4 2025 earnings call:

Sustainability of Medicare Advantage Margins and 2027 Rate Risk

Sentiment: Mixed

"while its disappointment in terms of the -- what we've seen is the preliminary rate for '27, we're committed to the Aetna margins, and that commitment remains unchanged. And we do not see this impacting our long-term enterprise guide that we provided in December during the Investor Day." — J. Joyner
"So specifically about 2027, the strategy, I'll just -- David said it, but I'll say it again, it remains unchanged. We are going to build on the momentum in 2026 and continue to drive the Medicare business back to target margins... notwithstanding the advanced rate notice, we think this, our business is well positioned." — Steven Nelson

Regulatory / Legislative Overhang on the PBM and Durability of Caremark Margins

Sentiment: Mixed

"what we've seen come through over the years is that we've been able to consistently earn what I believe are fair margins for the value the PBM delivers. That's not going to change with any of the things that you've seen presented... the good news is, is that we know, at least with the legislation, how to operate and how to run our business, and we have time to put the changes in place." — J. Joyner
"It's important to remember that TrueCost is built for transparency, durability and stable margins... we ultimately believe the margin profile will be similar and underlying growth for Caremark remains unchanged. We're excited about the shift to greater transparency and believe this recent legislation will accelerate adoption of TrueCost." — Ed DeVaney

Pharmacy & Consumer Wellness (Retail) Growth Durability and CostVantage Economics

Sentiment: Positive

"we have successfully completed the transition of cost-based reimbursement across commercial third-party discount, Medicare and Medicaid lines of business, and the cost-based pricing models are performing in line with our expectations... our results demonstrate that we are the best run pharmacy in the country." — Len Shankman
"While CostVantage is important in terms of the stable and durable profit margins in the business... we will be the consumer-based health care company in this country. And I think in large part because of the work that we're doing within our retail stores." — J. Joyner

Sentiment: Mixed

"we serve about 18 million [commercial] members. It's the highest membership level that we've served in the last decade actually... Fully insured remains pressure just due to the disciplined pricing approach... but that's been more than offset by growth in the self-funded business." — Steven Nelson
"we've been clear that trends are still very elevated, but we're not expecting that to change in '26... in Medicare, we expect another year of margin improvement... On the Medicaid side, I'd expect to maintain our cautious outlook... in Commercial, we've maintained pricing discipline, and as a result, I think you can expect performance in '26 will remain strong." — Brian Newman

Technology, AI, and the Open Engagement Platform: Investment Burden vs. Strategic Payoff

Sentiment: Positive

"AI... is being utilized across the enterprise... It's helping us with our cost and growth goals, allows us to reinvest in product innovation, including the open engagement platform... It will both drive savings as well as accelerate growth." — Brian Newman
"we believe we're uniquely positioned to create the next-generation of health care engagement... we continue to engage in productive conversations with potential partners... We plan to report our new product launches as well as partnership announcements in the coming quarters." — Prem Shah

Bull Case

CVS leverages MA margin recovery, resilient PBM economics, and scalable tech-enabled retail and engagement platforms to unlock its embedded earnings power and sustain mid-teens EPS growth through 2028.

Bear Case

Persistent regulatory and reimbursement pressure in MA and PBM, combined with elevated medical trends and heavy tech investment, prevent CVS from achieving target margins and its long-term earnings growth algorithm.

Looking Ahead

Investors will be closely watching CVS Health Corporation's next quarterly report for continued execution, particularly around sustainability of Medicare Advantage Margins and 2027 Rate Risk. With operating margins at 2.0%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was CVS Health Corporation's revenue in Q4 2025?

CVS Health Corporation reported Q4 2025 revenue of $105.7B, representing a +8.2% year-over-year change.

Did CVS Health Corporation beat earnings expectations in Q4 2025?

The stock moved -0.2% on earnings day, suggesting the results were roughly in line with market expectations. The current bull case centers on: CVS leverages MA margin recovery, resilient PBM economics, and scalable tech-enabled retail and engagement platforms to unlock its embedded earnings power and sustain mid-teens EPS growth through 2028.

What is the bull case for CVS stock?

The bull case for CVS centers on: CVS leverages MA margin recovery, resilient PBM economics, and scalable tech-enabled retail and engagement platforms to unlock its embedded earnings power and sustain mid-teens EPS growth through 2028.

What is the bear case for CVS stock?

The bear case for CVS centers on: Persistent regulatory and reimbursement pressure in MA and PBM, combined with elevated medical trends and heavy tech investment, prevent CVS from achieving target margins and its long-term earnings growth algorithm.

How has CVS stock performed since its Q4 2025 earnings?

CVS moved -0.2% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +7.1% since earnings. Year-to-date, the stock has returned -3.9%.

View all Healthcare Earnings Reports →

Browse all 400+ earnings reports →

Learn More

Analyze CVS in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for CVS Health Corporation and 400+ other stocks, explore the full platform.

Open CVS on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.